Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney

    NEW YORK, June 14 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE:
BMY) today acknowledged the statement by the Hon. Christopher J. Christie,
the U.S. Attorney for the District of New Jersey, regarding tomorrow's
expiration of the deferred prosecution agreement (DPA).
    During the past two years, Bristol-Myers Squibb has complied with the
letter and spirit of the DPA and has made significant enhancements to its
compliance structures and practices. The company believes its business
operations are stronger today as a result of having embraced a culture of
compliance. The expiration of the DPA will not diminish the company's
commitment to exemplary corporate citizenship, effective corporate
governance practices and the highest principles of integrity and
professionalism.
    Bristol-Myers Squibb is a global pharmaceutical and related healthcare
products company whose mission is to extend and enhance human life.

SOURCE Bristol-Myers Squibb

http://www.bms.com/
CONTACT:
Media, Laura Hortas, Communications,
+1-609-252-4587, laura.hortas@bms.com, or Tony Plohoros,
Communications, +1-609-252-7938, tony.plohoros@bms.com, both of
Bristol-Myers Squibb